Wells Fargo & Company Cuts DexCom (NASDAQ:DXCM) Price Target to $85.00

DexCom (NASDAQ:DXCM) had its price objective reduced by Wells Fargo & Company from $93.00 to $85.00 in a research note released on Friday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the medical device company’s stock.

Several other equities analysts have also issued reports on the company. Weiss Ratings raised DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, February 4th. TD Cowen reduced their price target on shares of DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Piper Sandler restated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Argus cut their target price on shares of DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Finally, Citigroup reissued a “buy” rating and issued a $77.00 price target (up previously from $75.00) on shares of DexCom in a research report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $85.27.

DexCom Stock Performance

Shares of DXCM stock opened at $70.02 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. The firm has a market cap of $26.95 billion, a P/E ratio of 33.34, a P/E/G ratio of 1.25 and a beta of 1.49. The firm’s 50 day moving average price is $69.03 and its 200-day moving average price is $69.47. DexCom has a one year low of $54.11 and a one year high of $93.25.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the previous year, the company earned $0.45 earnings per share. The firm’s quarterly revenue was up 13.1% compared to the same quarter last year. As a group, equities research analysts predict that DexCom will post 2.03 EPS for the current year.

Hedge Funds Weigh In On DexCom

A number of institutional investors and hedge funds have recently modified their holdings of DXCM. Andra AP fonden purchased a new stake in DexCom during the 2nd quarter worth about $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of DexCom during the 2nd quarter worth about $26,000. SJS Investment Consulting Inc. lifted its stake in DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after purchasing an additional 384 shares during the last quarter. Financial Consulate Inc. purchased a new stake in DexCom during the third quarter worth approximately $29,000. Finally, CVA Family Office LLC boosted its holdings in DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q4 results beat expectations: DexCom reported $0.68 EPS vs. $0.65 consensus and $1.26B in revenue (≈13% YoY); management reiterated 2026 guidance, supporting near-term outlook. Dexcom beats quarterly estimates
• Positive Sentiment: G7 15‑day sensor rollout and margin gains cited as growth drivers — management pointed to product adoption and improving margins as catalysts for revenue and profitability expansion. G7 rollout drives growth
• Positive Sentiment: Mizuho raised its price target to $90 (outperform), signaling confidence in longer‑term upside and helping buy‑side sentiment. Mizuho price target raise
• Positive Sentiment: BTIG reaffirmed a Buy rating with an $85 target, adding to analyst support that underpins the rally. BTIG reaffirmation
• Positive Sentiment: Product/AI initiative — the Stelo AI upgrade aims to deepen consumer metabolic-health engagement, which could expand recurring usage and ARPU over time. Stelo AI upgrade
• Neutral Sentiment: Analyst activity is mixed overall: several firms maintained or raised targets while at least one adjusted its price target (see below). This creates both support and some variability in near-term expectations. Wall Street analyst targets
• Neutral Sentiment: Trading indicators: intraday volume is notably above the stock’s average, which amplifies price moves but can increase short-term volatility. (Background market data)
• Neutral Sentiment: Short‑interest notices in the data feed show anomalous zero/NaN values and a 0.0 days‑to‑cover figure — the data appears unreliable and should be treated cautiously by traders monitoring short activity.
• Negative Sentiment: Wells Fargo trimmed its price target from $93 to $85 despite keeping an Overweight rating, a modest negative signal that reduces the high‑end analyst consensus. Wells Fargo target cut

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.